V. Domenyuk

Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets.

A. Barker, M. Famulok, G. Poste, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach

Heather A. O'Neill, D. Berry, John Quackenbush, 2017, Scientific Reports.

Identification of new DNA markers of endometrial cancer in patients from the Ukrainian population.

V. Domenyuk, V. Dubinina, K. Litovkin, 2007, Experimental oncology.

Whole-Virus Screening to Develop Synbodies for the Influenza Virus.

S. Johnston, C. Diehnelt, V. Domenyuk, 2016, Bioconjugate chemistry.

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

D. Berry, R. Greil, John Quackenbush, 2018, Nature Communications.

A Technology for Developing Synbodies with Antibacterial Activity

Valeriy Domenyuk, Stephen Albert Johnston, S. Johnston, 2013, PloS one.

A Simple Platform for the Rapid Development of Antimicrobials

P. Stafford, S. Johnston, Z. Cichacz, 2017, Scientific Reports.

Interleukin-6 -174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study.

V. Domenyuk, K. Litovkin, V. V. Bubnov, 2007, Experimental oncology.

Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.

M. Oberley, G. Fontanini, H. Lenz, 2021, European Journal of Cancer.

Marker Analysis of Quantitative Traits in Maize by ISSR–PCR

V. Domenyuk, Y. Sivolap, A. Belousov, 2002, Russian Journal of Genetics.